Simultaneously, imiquimod causes peripheral lymphocytes to express CXCR3, a homologous chemokine receptor that causes CD4+ T cells to infiltrate and accumulate within the tumor and is crucial for tumor rejection [130]. Here, CXCR3 is linked to neoplasm.